Investor Presentaiton

SAGA*: South Africa, Sub-Saharan Africa and Cipla Global Access ZAR Growth SA: 1 14% vs Q1 VS FY18 normalized for animal health South Africa Others Q1 Q-o-Q 125 44 38 +4% Q1 Y-o-Y $ Mn $ Mn +7% 125 127 116- 38 41 +14% 76 86 83 83 86 Cipla Q1 FY18 Q1 FY19 Q4 FY18 Key Business Highlights¹ Q1 FY19 Above market growth in South Africa private market; Cipla continues to outpace market growth at 15% vs 7% Cipla maintained its position as the 4th largest pharmaceutical company in the private market with 6% market share Strong momentum in Sereflo Synchrobreathe growing at 45% vs Q1FY18 First to market launches planned in Q2 including the first biosimilar Filgrastim Injection (Teva portfolio) 1 IQVIA (IMS) MAT Jun' 18. Investor Presentation: Q1FY19 08-08-2018 *Financial numbers are rounded off 9

View entire presentation